BiotechTube

CBL-514, placebo + CBL-514, placebo + CBL-514

Phase 1Completed
0 watching 0 views this week💤 Quiet
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Subcutaneous Fat

Conditions

Subcutaneous Fat

Trial Timeline

Nov 27, 2018 → Aug 20, 2019

NCT ID
NCT04699669

About CBL-514, placebo + CBL-514, placebo + CBL-514

CBL-514, placebo + CBL-514, placebo + CBL-514 is a phase 1 stage product being developed by Caliway Biopharmaceuticals for Subcutaneous Fat. The current trial status is completed. This product is registered under clinical trial identifier NCT04699669. Target conditions include Subcutaneous Fat.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04699669Phase 1Completed

Competing Products

9 competing products in Subcutaneous Fat

See all competitors
ProductCompanyStageHype Score
TR-701 FA + LinezolidMerckPhase 3
77
TR-701 FA + LinezolidMerckPhase 3
77
CBL-514Caliway BiopharmaceuticalsPhase 2
51
CBL-514 InjectionCaliway BiopharmaceuticalsPhase 2
51
CBL-514 InjectionCaliway BiopharmaceuticalsPhase 2
51
CBL-514 InjectionCaliway BiopharmaceuticalsPhase 3
76
CBL-514Caliway BiopharmaceuticalsPhase 2
51
CBL-514Caliway BiopharmaceuticalsPhase 2
51
CBL-514 injection + CBL-A1 Injection + CBL-A2 Injection + 0.9% Sodium ChlorideCaliway BiopharmaceuticalsPhase 2
51

Other Products from Caliway Biopharmaceuticals

CBL-514 InjectionPhase 3
76
CBL-514Phase 2
51
CBL-514 InjectionPhase 2
51
CBL-514 injectionPhase 2
51
CBL-514 InjectionPhase 2
51